The Interleukin 1 Receptor Associated Kinase 1 pipeline drugs market research report outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 1 Receptor Associated Kinase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Dermatology, and Undisclosed which include the indications Myelodysplastic Syndrome, Myelofibrosis, Psoriasis, Rheumatoid Arthritis, Diabetic Foot Ulcers, and Unspecified. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 1 Receptor Associated Kinase 1 pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 1, 1, 5, and 1 respectively.
Interleukin 1 Receptor Associated Kinase 1 overview
Interleukin-1 Receptor-Associated Kinase 1 (IRAK1) is a crucial signaling protein that plays a central role in the innate immune response. It is a member of the IRAK family and is involved in transducing signals downstream of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). Upon activation of TLRs or IL-1Rs by pathogen-associated molecular patterns (PAMPs) or cytokines, IRAK1 is recruited to the receptor complex. Subsequent phosphorylation events lead to the activation of IRAK1, initiating a signaling cascade that ultimately results in the activation of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs). These signaling pathways are crucial for the induction of pro-inflammatory cytokines and the coordination of the immune response against infections. Dysregulation of IRAK1 has been implicated in various inflammatory diseases and autoimmune disorders. Consequently, IRAK1 is considered a potential therapeutic target for conditions where aberrant immune activation contributes to pathology.
For a complete picture of Interleukin 1 Receptor Associated Kinase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
